Human papillomavirus type 16 L1 major capsid protein conformational epitopes (HPV16 L1 epitopes)

Human papillomavirus type 16 (HPV16) L1 major capsid protein conformational epitopes are the primary antigenic determinants recognized by the host immune system to neutralize the virus (NIH, 1996; NIH, 2004). The L1 protein spontaneously self-assembles into pentameric capsomeres, which further organize into icosahedral virus-like particles (VLPs) that mimic the native virion's surface (UniProt, 2016; NIH, 2012). These conformational epitopes, primarily located on the surface-exposed loops (BC, DE, EF, FG, and HI), are essential for the induction of high-titer neutralizing antibodies (NIH, 2025; NIH, 2004). Prophylactic vaccines, such as Gardasil and Cervarix, utilize recombinant L1 VLPs to elicit an immune response against these specific epitopes, effectively preventing HPV16 infection (CDC, 2024; CDC, 2025). Biologically, the L1 protein mediates the initial attachment of the virus to heparan sulfate proteoglycans on the basement membrane or cell surface, a process that triggers conformational changes necessary for viral entry (UniProt, 2016; NIH, 2026). Persistent infection with HPV16 is strongly associated with the development of cervical, anogenital, and oropharyngeal cancers, making these epitopes critical targets for cancer prevention (NIH, 1997; NCI, 2021).

Other names

HPV16 L1 capsid proteinHPV16 L1 VLPHuman papillomavirus type 16 L1 proteinHPV16 L1 major capsid proteinHPV16 L1 neutralizing epitopesHPV16 L1 surface loops

Induction of neutralizing antibodies that bind to conformational epitopes on the L1 protein, preventing viral attachment and entry into host cells (NIH, 2025; NIH, 2012).